Magali Toussaint
University of Lorraine
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Magali Toussaint.
Theranostics | 2015
Paul Retif; Magali Toussaint; Céline Frochot; Rima Chouikrat; Thierry Bastogne; Muriel Barberi-Heyob
This review focuses on the radiosensitization strategies that use high-Z nanoparticles. It does not establish an exhaustive list of the works in this field but rather propose constructive criticisms pointing out critical factors that could improve the nano-radiation therapy. Whereas most reviews show the chemists and/or biologists points of view, the present analysis is also seen through the prism of the medical physicist. In particular, we described and evaluated the influence of X-rays energy spectra using a numerical analysis. We observed a lack of standardization in preclinical studies that could partially explain the low number of translation to clinical applications for this innovative therapeutic strategy. Pointing out the critical parameters of high-Z nanoparticles radiosensitization, this review is expected to contribute to a larger preclinical and clinical development.
PLOS ONE | 2012
Hamanou Benachour; Thierry Bastogne; Magali Toussaint; Yosra Chemli; Aymeric Sève; Céline Frochot; François Lux; Olivier Tillement; Régis Vanderesse; Muriel Barberi-Heyob
Nanoparticles are widely suggested as targeted drug-delivery systems. In photodynamic therapy (PDT), the use of multifunctional nanoparticles as photoactivatable drug carriers is a promising approach for improving treatment efficiency and selectivity. However, the conventional cytotoxicity assays are not well adapted to characterize nanoparticles cytotoxic effects and to discriminate early and late cell responses. In this work, we evaluated a real-time label-free cell analysis system as a tool to investigate in vitro cyto- and photocyto-toxicity of nanoparticles-based photosensitizers compared with classical metabolic assays. To do so, we introduced a dynamic approach based on real-time cell impedance monitoring and a mathematical model-based analysis to characterize the measured dynamic cell response. Analysis of real-time cell responses requires indeed new modeling approaches able to describe suited use of dynamic models. In a first step, a multivariate analysis of variance associated with a canonical analysis of the obtained normalized cell index (NCI) values allowed us to identify different relevant time periods following nanoparticles exposure. After light irradiation, we evidenced discriminant profiles of cell index (CI) kinetics in a concentration- and light dose-dependent manner. In a second step, we proposed a full factorial design of experiments associated with a mixed effect kinetic model of the CI time responses. The estimated model parameters led to a new characterization of the dynamic cell responses such as the magnitude and the time constant of the transient phase in response to the photo-induced dynamic effects. These parameters allowed us to characterize totally the in vitro photodynamic response according to nanoparticle-grafted photosensitizer concentration and light dose. They also let us estimate the strength of the synergic photodynamic effect. This dynamic approach based on statistical modeling furnishes new insights for in vitro characterization of nanoparticles-mediated effects on cell proliferation with or without light irradiation.
Theranostics | 2017
Magali Toussaint; Florent Auger; Nicolas Durieux; Magalie Thomassin; Eloise Thomas; Albert Moussaron; Dominique Meng; François Plénat; Marine Amouroux; Thierry Bastogne; Céline Frochot; Olivier Tillement; François Lux; Muriel Barberi-Heyob
Despite recent progress in conventional therapeutic approaches, the vast majority of glioblastoma recur locally, indicating that a more aggressive local therapy is required. Interstitial photodynamic therapy (iPDT) appears as a very promising and complementary approach to conventional therapies. However, an optimal fractionation scheme for iPDT remains the indispensable requirement. To achieve that major goal, we suggested following iPDT tumor response by a non-invasive imaging monitoring. Nude rats bearing intracranial glioblastoma U87MG xenografts were treated by iPDT, just after intravenous injection of AGuIX® nanoparticles, encapsulating PDT and imaging agents. Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) allowed us an original longitudinal follow-up of post-treatment effects to discriminate early predictive markers. We successfully used conventional MRI, T2 star (T2*), Diffusion Weighted Imaging (DWI) and MRS to extract relevant profiles on tissue cytoarchitectural alterations, local vascular disruption and metabolic information on brain tumor biology, achieving earlier assessment of tumor response. From one day post-iPDT, DWI and MRS allowed us to identify promising markers such as the Apparent Diffusion Coefficient (ADC) values, lipids, choline and myoInositol levels that led us to distinguish iPDT responders from non-responders. All these responses give us warning signs well before the tumor escapes and that the growth would be appreciated.
Archive | 2015
Magali Toussaint; Muriel Barberi-Heyob; Sophie Pinel; Céline Frochot
PDT efficiency photosensitizers can be improved by different ways: development of targeted photosensitizers that also present rapid clearance from normal tissues, photosensitizers that own better photophysical properties (such as absorption in the red to use light that can better penetrate tissue, limited photobleaching), photosensitizers whose pharmacokinetics matched to the application, improve light equipments and the selective delivery of the activating light. In this chapter, our aim is to address how nanoparticles could be one of the solutions to improve PDT efficiency and to bypass the phenomena of resistance and limitations to PDT. We will describe how the use of nanoparticles can be positive for activation system, biodistribution properties, tumor selectivity by selecting judicious molecular and cellular targets.
Photodynamic Therapy and Photodiagnosis update | 2016
Mathieu Achard; Samir Acherar; Pierre Althuser; Jean-Claude Andre; Philippe Arnoux; Muriel Barberi-Heyob; Francis Baros; Thierry Bastogne; Cléo Boninsegna; Cédric Boura; Ludovic Colombeau; Céline Frochot; Valérie Juan-Hureaux; Stéphane Goria; Juliette Landon; Amirah Mohd Gazzali; Thibault Roques-Carmes; Noémie Thomas; Magali Toussaint; Régis Vanderesse; Zahraa Youssef
Photodynamic Therapy and Photodiagnosis update | 2016
Eloise Thomas; Magali Toussaint; Ludovic Colombeau; Céline Frochot; Régis Vanderesse; Amirah Mohd Gazzali; N Thomas-Jasniewski; Muriel Barberi-Heyob; François Lux; Olivier Tillement
Photodynamic Therapy and Photodiagnosis update | 2016
Magali Toussaint; Florent Auger; Magalie Thomassin; Eloise Thomas; Jean-Baptiste Tylcz; Philippe Arnoux; Olivier Tillement; François Lux; Céline Frochot; Muriel Barberi-Heyob
13e Colloque Nano-hybrides | 2016
Magali Toussaint; Florent Auger; Nicolas Durieux; Magalie Thomassin; Eloise Thomas; Albert Moussaron; Dominique Meng; François Plénat; Marine Amouroux; Jean-Baptiste Tylcz; Ernest Galbrun; Philippe Arnoux; Céline Frochot; Olivier Tillement; François Lux; Muriel Barberi-Heyob
International Congress on Photodynamic Applications, ICPA 2014 | 2014
Jean-Baptiste Tylcz; Thierry Bastogne; Alexia Bourguignon; Magali Toussaint; Céline Frochot; Muriel Barberi-Heyob
10th International Symposium on Photodynamic Therapy and Photodiagnosis in Clinical Practice | 2014
Magali Toussaint; Florent Auger; Nicolas Durieux; Magalie Thomassin; Thierry Bastogne; Céline Frochot; Serge Mordon; Muriel Barberi-Heyob